352 related articles for article (PubMed ID: 10853928)
1. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
Centofanti M; Manni G; Gregori D; Cocco F; Lorenzano D; Bucci MG
Graefes Arch Clin Exp Ophthalmol; 2000 Apr; 238(4):302-5. PubMed ID: 10853928
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Simmons ST;
Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
[TBL] [Abstract][Full Text] [Related]
5. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
[TBL] [Abstract][Full Text] [Related]
6. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
[TBL] [Abstract][Full Text] [Related]
7. The short-term IOP-lowering effect of brimonidine 0.2% and dorzolomide 2% combination in primary open-angle glaucoma.
Ermis SS; Ozturk F; Inan UU
Acta Ophthalmol Scand; 2002 Dec; 80(6):632-4. PubMed ID: 12485285
[TBL] [Abstract][Full Text] [Related]
8. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
10. [Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers].
Carrasco Font C; Arias Puente A; García Sáenz MC; Villarejo Díaz-Maroto I
Arch Soc Esp Oftalmol; 2004 Apr; 79(4):163-8. PubMed ID: 15124072
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group.
Boyle JE; Ghosh K; Gieser DK; Adamsons IA
Ophthalmology; 1998 Oct; 105(10):1945-51. PubMed ID: 9787368
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
14. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
García Sanchez J
Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
[TBL] [Abstract][Full Text] [Related]
16. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
Simmons ST; Earl ML;
Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
[TBL] [Abstract][Full Text] [Related]
17. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
Lee DA; Gornbein JA
J Glaucoma; 2001 Jun; 10(3):220-6. PubMed ID: 11442187
[TBL] [Abstract][Full Text] [Related]
20. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]